Última actualización:
4/8/2025
Años publicados: 1996, 2003, 2025
NORD gratefully acknowledges Gioconda Alyea, MD (FMG), MS, National Organization for Rare Disorders, for assistance in the preparation of this report.
Summary
Fontaine progeroid syndrome is a very rare condition that affects many parts of the body. It can cause poor growth, changes in the shape of the bones and face, and skin that is thin, sagging, and appears older than normal (progeroid appearance). This aged appearance is most noticeable in babies and young children but tends to improve as they grow older. 1
People with Fontaine progeroid syndrome may have specific features like a short, round head shape, large soft spots on the skull, and abnormalities in the tips of the fingers. Other problems may include heart issues, differences in urinary or reproductive organs, eye problems, or stomach and digestive system issues.1
This condition is caused by changes (disease-causing variants) in the SLC25A24 gene. These gene variants occur randomly in most cases, meaning that in most people the condition is not inherited from parents.
There is no cure for Fontaine progeroid syndrome, but many of the symptoms can be treated or managed. 1
Introduction
Fontaine progeroid syndrome was previously described under other names such as “Gorlin-Chaudhry-Moss syndrome”, “Fontaine-Farriaux syndrome” and “Petty syndrome”. Doctors now know that these conditions share the same underlying genetic cause and are all part of “SLC25A24 Fontaine progeroid syndrome” or Fontaine progeroid syndrome. 1,2
Fontaine progeroid syndrome is characterized by an abnormal skull shape, distinctive face and an appearance of premature aging that is sometime described as progeroid. The signs and symptoms of Fontaine progeroid syndrome may include: 1,2,3,4,5,6,7,8
Fontaine progeroid syndrome is mainly caused by changes (disease-causing variants or pathogenic variants) in the SLC25A24 gene. This gene provides instructions for making a protein that helps transport important molecules, including ATP (the body’s main energy source), across the inner membrane of mitochondria. Mitochondria are like tiny power plants inside cells, responsible for producing energy and supporting essential cell functions, like building proteins and breaking down molecules for the body to use.1,8
SLC25A24 gene variants change the structure of the protein, making it less effective at transporting molecules across the mitochondrial membrane. This leads to several problems:1,6,8
These energy problems and increased cell death are likely responsible for many of the signs and symptoms of Fontaine progeroid syndrome, like abnormal growth and connective tissue issues, though scientists are still working to understand the exact link between these changes and the specific symptoms people experience.
In some people with the syndrome, no variants in the SLC25A24 gene are found, suggesting that variants in other, still unknown genes may also cause the condition.
Fontaine progeroid syndrome is inherited in an autosomal dominant pattern. Dominant genetic disorders occur when only a single copy of a disease-causing gene variant is necessary to cause the disease. This means only one variant copy of the SLC25A24 gene is enough to cause the condition. The gene variant can be inherited from either parent or can be the result of a new (de novo) changed gene in the affected individual that is not inherited. The risk of passing the gene variant from an affected parent to a child is 50% for each pregnancy. The risk is the same for males and females.
In most cases of Fontaine progeroid syndrome, the variant is de novo, meaning it happens for the first time in the child and wasn’t inherited from the parents. When a variant is de novo, the chance of having another child with the same syndrome is generally very low.
However, there is a small chance (~1%) for the condition to be transmitted to a child if one of the parents has germline mosaicism, a rare situation where some of one parent’s reproductive cells carry the variant, even though the rest of their body cells do not. Because of this small possibility, genetic counseling and options like prenatal or pre-implantation genetic testing may be offered to families who are considering having more children.1
Fontaine progeroid syndrome is extremely rare, with an estimated prevalence of less than 1 in 1,000,000.7As of 2024, only 13 individuals worldwide have been confirmed to have Fontaine progeroid syndrome through genetic testing.1
Doctors suspect the diagnosis based on the signs and symptoms mentioned above, such as growth problems, skin problems, facial features, skull shape, hair patterns, hernia, finger and toe differences and abnormal genitalia.
Genetic testing identifying a variant in the SLC25A24 gene confirms the diagnosis 1
Treatment
There is no cure for Fontaine progeroid syndrome but many of the symptoms can be treated or managed. Affected people may need to be treated by a team of multiple specialists including a craniofacial clinic (involving plastic surgery, neurosurgery and otolaryngology), cardiology, pulmonology, gastroenterology and clinical genetics.
While there are no official guidelines for treating this condition, doctors recommend personalized care based on a person’s symptoms and needs.
After a diagnosis is made, the following evaluations are suggested to evaluate all the problems that the affected person may have:1
Families may benefit from social work, parent support groups, or home nursing services.
Management and treatment are focused on relieving symptoms and improving quality of life.
Affected people need to be consulted and followed by several specialists who should work together as a team for the best management.
Regular checkups are important to monitor health and catch any new issues early. Height, weight and head size should be measured at every visit. Echocardiograms are recommended at least every three years or more often if problems are found. Annual hearing and eye checkups are recommended. Progress in motor skills, learning and language should be assessed regularly.
It is recommended to avoid contact sports or any activities that may harm the skull or aorta (a major blood vessel) should be avoided. Heavy lifting or straining may increase the risk of complications, especially if the aorta is enlarged.
Aerobic exercise, such as walking or swimming, is encouraged if there are no restrictions from a doctor.
Families may benefit from connecting with parent support groups or online communities, as well as working with a social worker for additional help with caregiving or accessing resources.
Information on current clinical trials is posted on the Internet at https://clinicaltrials.gov/ All studies receiving U.S. Government funding, and some supported by private industry, are posted on this government web site.
For information about clinical trials being conducted at the NIH Clinical Center in Bethesda, MD, contact the NIH Patient Recruitment Office:
Tollfree: (800) 411-1222
TTY: (866) 411-1010
Email: [email protected]
Some current clinical trials also are posted on the following page on the NORD website:
https://rarediseases.org/living-with-a-rare-disease/find-clinical-trials/
For information about clinical trials sponsored by private sources, contact:
http://www.centerwatch.com/
For information about clinical trials conducted in Europe, contact:
https://www.clinicaltrialsregister.eu/
NORD y la Fundación MedicAlert se han asociado en un nuevo programa para brindar protección a pacientes con enfermedades raras en situaciones de emergencia.
Aprende más https://rarediseases.org/patient-assistance-programs/medicalert-assistance-program/Asegurarse de que los pacientes y los cuidadores estén equipados con las herramientas que necesitan para vivir su mejor vida mientras manejan su condición rara es una parte vital de la misión de NORD.
Aprende más https://rarediseases.org/patient-assistance-programs/rare-disease-educational-support/Este programa de asistencia, primero en su tipo, está diseñado para los cuidadores de un niño o adulto diagnosticado con un trastorno raro.
Aprende más https://rarediseases.org/patient-assistance-programs/caregiver-respite/The information provided on this page is for informational purposes only. The National Organization for Rare Disorders (NORD) does not endorse the information presented. The content has been gathered in partnership with the MONDO Disease Ontology. Please consult with a healthcare professional for medical advice and treatment.
The Genetic and Rare Diseases Information Center (GARD) has information and resources for patients, caregivers, and families that may be helpful before and after diagnosis of this condition. GARD is a program of the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH).
View reportOrphanet has a summary about this condition that may include information on the diagnosis, care, and treatment as well as other resources. Some of the information and resources are available in languages other than English. The summary may include medical terms, so we encourage you to share and discuss this information with your doctor. Orphanet is the French National Institute for Health and Medical Research and the Health Programme of the European Union.
View reportOnline Mendelian Inheritance In Man (OMIM) has a summary of published research about this condition and includes references from the medical literature. The summary contains medical and scientific terms, so we encourage you to share and discuss this information with your doctor. OMIM is authored and edited at the McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine.
View report